###begin article-title 0
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The secretory phospholipase A2 group IIA: a missing link between inflammation, activated renin-angiotensin system, and atherogenesis?
###end article-title 0
###begin p 1
###xml 245 246 245 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 252 253 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 533 534 533 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 903 904 903 904 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1227 1228 1227 1228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1411 1412 1411 1412 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1498 1499 1498 1499 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1031 1039 <span type="species:ncbi:9606">patients</span>
Inflammation, lipid peroxidation and chronic activation of the rennin - angiotensin system (RAS) are hallmarks of the development of atherosclerosis. Recent studies have suggested the involvement of the pro-inflammatory secretory phospholipase A2 (sPLA2)-IIA in atherogenesis. This enzyme is produced by different cell types through stimulation by pro-inflammatory cytokines. It is detectable in the intima and in media smooth muscle cells, not only in atherosclerotic lesions but also in the very early stages of atherogenesis. sPLA2-IIA can hydrolyse the phospholipid monolayers of low density lipoproteins (LDL). Such modified LDL show increased affinity to proteoglycans. The modified particles have a greater tendency to aggregate and an enhanced ability to insert cholesterol into cells. This modification may promote macrophage LDL uptake leading to the formation of foam cells. Furthermore, sPLA2-IIA is not only a mediator for localized inflammation but may be also used as an independent predictor of adverse outcomes in patients with stable coronary artery disease or acute coronary syndromes. An interaction between activated RAS and phospholipases has been indicated by observations showing that inhibitors of sPLA2 decrease angiotensin (Ang) II-induced macrophage lipid peroxidation. Meanwhile, various interactions between Ang II and oxLDL have been demonstrated suggesting a central role of sPLA2-IIA in these processes and offering a possible target for treatment. The role of sPLA2-IIA in the perpetuation of atherosclerosis appears to be the missing link between inflammation, activated RAS and lipidperoxidation.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 183 192 183 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b72">Ross 1999</xref>
###xml 484 501 484 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">Neaton et al 1992</xref>
###xml 503 518 503 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">Lowe et al 1998</xref>
###xml 520 537 520 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b84">Thomas et al 2002</xref>
###xml 762 782 762 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b83">Taniguchi et al 2005</xref>
Atherosclerosis with its associated cardiovascular events, myocardial infarction (MI), sudden cardiac death or stroke, is one of the leading causes of death in the western countries (Ross 1999). Inflammation and lipid peroxidation, as well as chronic activation of the renin-angiotensin system (RAS), are hallmarks of atherogenesis. Activated RAS, inflammatory processes and lipid peroxidaton products contribute to the initiation, progression and rupture of atherosclerotic plaques (Neaton et al 1992; Lowe et al 1998; Thomas et al 2002). Therefore reducing pro-inflammatory mediators, and inhibiting the modulation of their releasing pathways, may be important both for the stability of atherosclerotic lesions and the perpetuation of atherosclerotic plaques (Taniguchi et al 2005).
###end p 3
###begin p 4
###xml 204 223 204 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">Nickenig et al 2000</xref>
###xml 299 300 299 300 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 306 307 306 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 397 415 397 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">Kovanen et al 2000</xref>
###xml 417 439 417 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">Hurt-Camejo et al 2001</xref>
###xml 441 459 441 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63">Niessen et al 2003</xref>
###xml 461 478 461 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b86">Tietge et al 2005</xref>
###xml 480 504 480 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">Menschikowski et al 2006</xref>
###xml 573 574 573 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 647 666 647 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">Murakami et al 2004</xref>
###xml 668 689 668 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b71">Rosengreen et al 2004</xref>
###xml 691 712 691 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b91">Wooton-Kee et al 2004</xref>
###xml 771 772 771 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 788 789 788 789 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 868 882 868 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b79">Six et al 2000</xref>
###xml 884 899 884 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">Kudo et al 2002</xref>
###xml 901 918 901 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">Jaross et al 2002</xref>
###xml 998 999 998 999 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1223 1240 1223 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">Keidar et al 1997</xref>
###xml 1242 1258 1242 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">Hayek et al 2000</xref>
###xml 1260 1281 1260 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">Luchtefeld et al 2006</xref>
###xml 1283 1306 1283 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">Divchev et al pers comm</xref>
###xml 606 612 <span type="species:ncbi:10090">murine</span>
###xml 616 621 <span type="species:ncbi:9606">human</span>
###xml 798 803 <span type="species:ncbi:9606">human</span>
In addition to this link, more direct interactions have been suggested between a chronically activated RAS, and elevated pro-inflammatory cytokines and lipoproteins, which may also promote atherogenesis (Nickenig et al 2000). An increasing amount of evidence indicates that secretory phospholipase A2 (sPLA2) enzymes present in the vessel wall have localized effects that promote these processes (Kovanen et al 2000; Hurt-Camejo et al 2001; Niessen et al 2003; Tietge et al 2005; Menschikowski et al 2006). Three members (group IIA, group V and group X) of the various sPLA2 isozymes have been detected in murine or human atherosclerotic lesions (Murakami et al 2004; Rosengreen et al 2004; Wooton-Kee et al 2004); expression and localization of secretory phospholipase A2 group IIA (sPLA2-IIA) in human atherosclerotic tissue have been the best documented until now (Six et al 2000; Kudo et al 2002; Jaross et al 2002). In this context, recent investigations have suggested the involvement of sPLA2-IIA as part of a systemic and localized acute-phase-reaction in the development of atherosclerosis, not only as a specific marker of inflammation but probably as a central link between activated RAS and lipid peroxidation (Keidar et al 1997; Hayek et al 2000; Luchtefeld et al 2006; Divchev et al pers comm).
###end p 4
###begin p 5
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
This study explains the importance of sPLA2-IIA as a key enzyme of inflammation-based atherosclerotic development, and a prognostic marker of cardiovascular events, based on current literature and the experimental findings of our group.
###end p 5
###begin title 6
###xml 40 41 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
What are phospholipases (in general sPLA2s) good for?
###end title 6
###begin p 7
###xml 471 485 471 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b79">Six et al 2000</xref>
###xml 487 502 487 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">Kudo et al 2002</xref>
###xml 534 535 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 540 541 540 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 248 254 <span type="species:ncbi:9606">humans</span>
Phospholipases are enzymes that play a crucial role in the metabolism of phospholipids. Various groups and a remarkable number of subgroups have been identified, but specific functions for only some of these phospholipases have been established in humans. Their classification is related to the site of action on the phospholipid molecules. In this context, phospholipases may act as acylhydrolases (PLAs and PLB), lysophospholipases or phosphodiesterases (PLC and PLD) (Six et al 2000; Kudo et al 2002). For example, phospholipases A2 (PLA2s) catalyze the sn-2 ester bonds of glycerophospholipids and, more importantly, appear to be the most influential subfamily in pro-inflammatory processes and thereby in inflammation-initiated diseases.
###end p 7
###begin p 8
###xml 247 261 247 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b79">Six et al 2000</xref>
###xml 263 278 263 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">Kudo et al 2002</xref>
###xml 280 297 280 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">Jaross et al 2002</xref>
###xml 316 317 316 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 333 335 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 403 404 399 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 410 411 406 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 419 430 411 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">Leslie 1997</xref>
###xml 432 446 424 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">Bonventre 1999</xref>
###xml 474 492 466 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66">Pickard et al 1999</xref>
###xml 509 511 501 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 527 528 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 535 536 527 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 540 559 532 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">Balsinde et al 1997</xref>
This subfamily can be characterized as a group of calcium-dependent lipolytic enzymes with a preserved calcium-binding loop and a His-Asp diad at the catalytic site. More then 13 groups and up to 20 different subgroups have been described so far (Six et al 2000; Kudo et al 2002; Jaross et al 2002). Nonsecretory PLA2s include the Ca2+-sensitive arachidonoyl-selective 85-kDa group IValpha cytosolic PLA2 (cPLA2alpha) (Leslie 1997; Bonventre 1999), paralogs of this enzyme (Pickard et al 1999), and several Ca2+-independent PLA2s (iPLA2s) (Balsinde et al 1997).
###end p 8
###begin p 9
###xml 32 33 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 51 52 51 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 82 106 82 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65">Pfeilschifter et al 1989</xref>
###xml 108 129 108 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b76">Schalkwijk et al 1991</xref>
###xml 156 173 156 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60">Nakano et al 1990</xref>
###xml 175 194 175 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">Kurihara et al 1991</xref>
###xml 216 235 216 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">Murakami et al 1993</xref>
###xml 249 268 249 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">Hayakawa et al 1988</xref>
###xml 283 300 283 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">Foneth et al 1994</xref>
###xml 302 318 302 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b68">Reddy et al 1996</xref>
###xml 334 351 334 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b92">Wright et al 1990</xref>
###xml 367 382 367 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">Hidi et al 1993</xref>
###xml 384 402 384 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">Brabour et al 1993</xref>
###xml 404 419 404 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b89">Vial et al 1995</xref>
###xml 441 457 441 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">Crowl et al 1991</xref>
Many cell types can secrete sPLA2s, especially sPLA2-IIA such as mesangial cells (Pfeilschifter et al 1989; Schalkwijk et al 1991), vascular smooth muscle (Nakano et al 1990; Kurihara et al 1991), endothelial cells (Murakami et al 1993), platelets (Hayakawa et al 1988), mast cells (Foneth et al 1994; Reddy et al 1996), neutrophils (Wright et al 1990), macrophages (Hidi et al 1993; Brabour et al 1993; Vial et al 1995), and hepatic cells (Crowl et al 1991).
###end p 9
###begin p 10
###xml 251 252 251 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 277 278 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 525 539 521 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">Bonventre 1999</xref>
###xml 541 560 537 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b88">Valentin et al 1999</xref>
###xml 562 583 558 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b73">Sapirstein et al 2000</xref>
###xml 585 603 581 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">Granata et al 2003</xref>
###xml 626 627 622 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 807 808 803 804 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 918 919 914 915 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1134 1151 1130 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b92">Wright et al 1990</xref>
###xml 1153 1169 1149 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">Laine et al 1999</xref>
Several pro-inflammatory stimuli may lead to secretion of diverse enzymes including phospholipases as part of a host defense mechanism. Such stimuli could be microbial pathogens as well as chemical irritants, allergens or physical stress factors. CPLA2alpha as well as the sPLA2s have been involved in various physiological and pathological functions such as release of pro-inflammatory mediators, cell proliferation, ischemic injury, inflammatory and allergic disease, lipid modification, cancer, and antibacterial defense (Bonventre 1999; Valentin et al 1999; Sapirstein et al 2000; Granata et al 2003). The presence of sPLA2-IIA activity in tears or seminal plasma, which may come into contact with bacterial pathogens, also suggests primary antibacterial properties of these enzymes. In this sense, sPLA2-IIA is able to destroy the membranes of Gram-positive bacteria. Interestingly, in Gram-negative bacteria sPLA2-IIA cannot directly attack the phospholipids of the intact cell membranes, but needs the cooperative action of neutrophils which produce bactericidal permeability-increasing protein (BPI) to support this function (Wright et al 1990; Laine et al 1999). Phospholipases could therefore act in the frame of combined inflammation associated humoral and cellular responses.
###end p 10
###begin p 11
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 216 217 216 217 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 232 233 228 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 266 267 258 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 288 289 280 281 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 401 418 393 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">Balboa et al 1996</xref>
###xml 420 436 412 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b69">Reddy et al 1997</xref>
###xml 438 458 430 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b67">Pruzanski et al 1998</xref>
###xml 516 517 508 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 523 524 515 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 534 535 526 527 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 619 633 611 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">Han et al 2003</xref>
###xml 763 764 755 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 810 829 802 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">Murakami et al 2004</xref>
###xml 831 851 823 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b71">Rosengren et al 2004</xref>
###xml 853 874 845 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b91">Wooton-Kee et al 2004</xref>
###xml 876 885 868 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b90">Webb 2005</xref>
###xml 768 774 <span type="species:ncbi:10090">murine</span>
###xml 779 784 <span type="species:ncbi:9606">human</span>
SPLA2s do not exhibit acyl chain specificity, whereas a preferential effect on arachidonic acid (AA)-containing membrane phospholipids, compared with those containing other fatty acids, could be demonstrated for cPLA2alpha. The cPLA2alpha, group IIA, and group V PLA2s are the primary PLA2s responsible for producing AA and its metabolites in endothelial, fibroblastic mast and macrophage cell lines (Balboa et al 1996; Reddy et al 1997; Pruzanski et al 1998). A profound cross-talk between cytosolic phospholipase A2 (cPLA2) and sPLA2-IIA with regard to free radical release has been confirmed by some investigations (Han et al 2003). Immunohistochemistry studies have further demonstrated the presence of group IIA, group V and group X secretory phospholipase A2 in murine and human atherosclerotic lesions (Murakami et al 2004; Rosengren et al 2004; Wooton-Kee et al 2004; Webb 2005).
###end p 11
###begin p 12
###xml 394 410 394 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">Green et al 1991</xref>
###xml 412 428 412 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b87">Vadas et al 1993</xref>
###xml 462 463 462 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 584 602 584 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">de Beer et al 1997</xref>
###xml 604 622 604 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">Ivandic et al 1999</xref>
###xml 624 648 624 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">Menschikowski et al 2000</xref>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
On the other hand, it could be shown that there are changes in serum cholesterol levels with decreased concentrations of high density (HDL) and low density lipoproteins (LDL) in patients suffering from generalized infectious diseases such as sepsis. Moreover, a frequent finding in patients with persisting infections, metastatic tumors or chronic inflammatory diseases is hypocholesterolemia (Green et al 1991; Vadas et al 1993). The serum concentration of sPLA2-IIA, especially the activity of the enzyme, is markedly increased in these diseases, acting as an acute-phase-reactant (de Beer et al 1997; Ivandic et al 1999; Menschikowski et al 2000).
###end p 12
###begin p 13
###xml 223 224 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 230 247 219 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">Peilot et al 2000</xref>
###xml 249 273 238 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">Menschikowski et al 2000</xref>
###xml 275 293 264 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Antonio et al 2002</xref>
###xml 475 476 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 628 646 617 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">de Beer et al 1997</xref>
###xml 648 666 637 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">Ivandic et al 1999</xref>
###xml 668 692 657 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">Menschikowski et al 2000</xref>
###xml 694 711 683 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">Jaross et al 2002</xref>
In acute or chronic inflammatory states, serum levels of pro-inflammatory cytokines, such as interleukin (IL)-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and interferon (IFN)-gamma are also increased and may induce sPLA2-IIA (Peilot et al 2000; Menschikowski et al 2000; Antonio et al 2002). These pro-inflammatory cytokines can also be released at an increased rate by the liver and locally by other cells especially within the atherosclerotic plaque. Such increased PLA2-activity in serum is thought to lead to a more efficient clearance of lipoproteins mainly through the liver, thereby resulting in hypocholesterolemia (de Beer et al 1997; Ivandic et al 1999; Menschikowski et al 2000; Jaross et al 2002).
###end p 13
###begin p 14
###xml 179 180 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Therefore, early evidence suggested the existence of a central link between systemic as well as local inflammatory processes and lipid metabolism, and that this link could be sPLA2-IIA.
###end p 14
###begin title 15
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The secretory phospholipase A2, group IIA role in atherogenesis
###end title 15
###begin p 16
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The key role played by sPLA2-IIA in the development of atherosclerosis, not merely as a mediator for localized inflammation, has been indicated by a number of recent in-vitro and in-vivo studies as follows. The enzyme seems to play an important role as an integral modulator at several stages of atherogenesis.
###end p 16
###begin p 17
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 103 125 103 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">Hurt-Camejo et al 2001</xref>
###xml 146 147 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 228 245 228 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b70">Romano et al 1998</xref>
###xml 247 265 247 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b74">Sartipy et al 1998</xref>
###xml 459 460 459 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 518 535 518 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b70">Romano et al 1998</xref>
###xml 580 581 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 742 766 735 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">Menschikowski et al 2000</xref>
###xml 768 785 761 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">Peilot et al 2000</xref>
###xml 787 805 780 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">Antonio et al 2002</xref>
###xml 212 217 <span type="species:ncbi:9606">human</span>
###xml 672 677 <span type="species:ncbi:9606">human</span>
In the arterial wall, sPLA2, especially sPLA2-IIA, may exert proatherogenic effects in multiple steps (Hurt-Camejo et al 2001). The isoenzyme sPLA2-IIA is located mainly in vascular smooth muscle cells of normal human arteries (Romano et al 1998; Sartipy et al 1998). In contrast, in atherosclerotic plaques the enzyme is detectable within the lipid cores, in macrophage-rich regions and in the extracellular matrices of the affected intima. Furthermore, sPLA2-IIA has a close spatial relationship to collagen fibres (Romano et al 1998). As mentioned above, the expression of sPLA2-IIA in these cells is assumed to be up-regulated in vitro by several cytokines present in human atherosclerotic lesions, including IL-1beta, TNF-alpha and IFN (Menschikowski et al 2000; Peilot et al 2000; Antonio et al 2002).
###end p 17
###begin p 18
###xml 156 157 156 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 296 297 296 297 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
One of the first important features in atherogenesis is the retention of LDL particles in the subendothelial space. The modification of LDL mediated by sPLA2-IIA can change the structural organisation of the LDL particle leading to more pronounced lipid accumulation in the vessel wall. Such sPLA2-IIA modified LDL are characterized through an increased affinity for proteoglycans.
###end p 18
###begin p 19
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 110 125 110 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b93">Yuan et al 1995</xref>
###xml 127 144 127 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">Arbibe et al 1998</xref>
###xml 146 165 146 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">Fourcade et al 1998</xref>
###xml 167 189 167 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">Hurt-Camejo et al 2001</xref>
###xml 191 213 191 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">Hurt-Camejo et al 2001</xref>
###xml 367 385 367 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b81">Sparrow et al 1988</xref>
###xml 387 407 387 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">Leitinger et al 1999</xref>
###xml 438 439 438 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 741 758 741 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b80">Snitko et al 1997</xref>
As a result of the hydrolytic activity, sPLA2-IIA releases free fatty acids and lyso-phosphatidylcholine(PC) (Yuan et al 1995; Arbibe et al 1998; Fourcade et al 1998; Hurt-Camejo et al 2001; Hurt-Camejo et al 2001). This action may affect the functions and properties of vascular endothelial and smooth muscle cells, and of macrophages, at sites of LDL accumulation (Sparrow et al 1988; Leitinger et al 1999). It should be noted that sPLA2-IIA prefers phosphatidic acid (PA) as substrate over other phospholipids found in plasma membranes including phosphatidylserine (PS), phosphatidylcholine (PC) and phosphatidylethanolamine (PE). Sintko and colleagues reported the following order of substrate preference: PA > PE approximately PS > PC (Snitko et al 1997).
###end p 19
###begin p 20
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 113 114 113 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 308 309 308 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 330 346 330 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">Eckey et al 1997</xref>
###xml 396 397 396 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 516 517 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 540 558 540 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b75">Sartipy et al 2000</xref>
The ability of sPLA2-IIA to hydrolyze PC seems to be weak, but several conditions may amplify that function. sPLA2-IIA acts on oxidized (ox-)LDL more efficiently by transforming LDL to a more atherogenic form. This action is based on the fact that oxidative modification of phospholipids increases their sPLA2-IIA susceptibility (Eckey et al 1997). Furthermore, the closed spatial contact of sPLA2-IIA with matrix proteoglycans (in general decorin, biglycan and versican) may increase the hydrolytic activity of sPLA2-IIA toward PC in LDL (Sartipy et al 2000).
###end p 20
###begin p 21
###xml 14 15 14 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 219 236 219 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">Hakala et al 2001</xref>
###xml 347 348 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 429 448 429 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">Heinecke et al 1991</xref>
###xml 450 467 450 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">Aviram et al 1992</xref>
Moreover, sPLA2-IIA modified proteoglycan-bound lipoproteins show a greater tendency to aggregation and fusion. The result is a progressive deposition of lipids within the extracellular matrices of the arterial intima (Hakala et al 2001). In addition to enhancing the retention of LDL particles in the vessel wall, there is also evidence that sPLA2 modification may promote macrophage LDL uptake, leading to foam cell formation (Heinecke et al 1991; Aviram et al 1992).
###end p 21
###begin p 22
###xml 201 202 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 208 226 208 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">Bezzine et al 2000</xref>
###xml 228 247 228 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">Hanasaki et al 2002</xref>
###xml 249 269 249 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">Gesquiere et al 2002</xref>
###xml 307 308 307 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 556 557 556 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 641 665 641 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b58">Murakami and Kudo (2003)</xref>
###xml 682 683 682 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 691 692 691 692 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 776 777 776 777 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 839 858 839 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">Hanasaki et al 2002</xref>
###xml 860 879 860 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b58">Murakami et al 2003</xref>
###xml 920 921 920 921 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 983 999 983 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b77">Shoda et al 1999</xref>
###xml 76 81 <span type="species:ncbi:9606">human</span>
It should be noted that other sPLA isoenzymes detectable in circulation and human atherosclerotic lesions, especially of group V and group X, have more potent actions on lipoproteins compared with sPLA2-IIA (Bezzine et al 2000; Hanasaki et al 2002; Gesquiere et al 2002). Obviously, the sole potency of sPLA2-IIA in hydrolyzing the primary substrates phosphatidylethanolamine and phosphatidylserine may not be the only important feature in atherosclerotic plaque perpetuation, especially in transforming LDL into more atherogenic forms. Interestingly, sPLA2-V has a preferential action in hydrolysis of HDL compared with LDL, as reviewed by Murakami and Kudo (2003). Similar to sPLA2-V, sPLA2-X definitely shows more pronounced PC-hydrolysing activity. On the other hand, sPLA2-X modified LDL particles have a lower tendency to aggregate (Hanasaki et al 2002; Murakami et al 2003). Nevertheless, we can suppose that sPLA2 isoenzymes may act synergistically under certain conditions (Shoda et al 1999).
###end p 22
###begin p 23
###xml 180 181 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 307 308 307 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 512 529 512 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">deBeer et al 2000</xref>
###xml 668 669 668 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 740 757 740 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b85">Tietge et al 2000</xref>
Together, HDL and apolipoprotein A-I(apoA-I) are positive prognostic factors in preventing perpetuation of arteriosclerotic plaque formation; there is increasing evidence that sPLA2-IIA may transform these particles to pro-atherogenic and pro-inflammatory reactants. As shown by de Beer and colleagues, sPLA2-IIA dependent hydrolysis of HDL results in a more efficient scavenger receptor class B type I cholesteryl ester uptake, leading to an accelerated HDL catabolism in the kidney during inflammatory states (deBeer et al 2000). Moreover, HDL- and ApoA-I-catabolism as well as HDL-cholesteryl ester tissue uptake were significantly enhanced under conditions of sPLA2-IIA overexpression even in the absence of inflammatory preconditions (Tietge et al 2000).
###end p 23
###begin p 24
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 189 190 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 269 270 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 328 343 328 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b82">Tada et al 1998</xref>
###xml 389 390 389 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 462 481 462 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b78">Silliman et al 2002</xref>
###xml 533 547 533 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">Han et al 2003</xref>
###xml 582 602 582 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">Hernandez et al 1998</xref>
The above mentioned effects promoted by sPLA2-IIA - in general the release of AA - are primarily based on increased enzyme activity. However, the noteworthy non-enzymatic properties of sPLA2-IIA can also contribute to atherogenesis. In this way, catalytic inactive sPLA2-IIA was shown to promote COX-2 expression in mast cells (Tada et al 1998). Further effects may be mediated by the sPLA2 M-type receptor on smooth muscle cells independent of enzyme activity (Silliman et al 2002) and by activating signaling pathways such as ERK (Han et al 2003) MAP kinases or protein kinase C (Hernandez et al 1998). Further research is needed to make clear whether these effects are present in atherosclerotic lesions, and how far they may contribute to atherogenesis.
###end p 24
###begin title 25
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
sPLA2-IIA as a prognostic marker in coronary artery disease
###end title 25
###begin p 26
###xml 72 73 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 239 258 239 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">Kugiyama et al 1999</xref>
###xml 302 303 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 495 509 495 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">Liu et al 2003</xref>
###xml 540 541 540 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 661 691 661 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">Kugiyama and colleagues (2000)</xref>
###xml 724 725 724 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 853 872 853 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">Kugiyama et al 2000</xref>
###xml 875 903 875 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">Mallat and colleagues (2007)</xref>
###xml 959 960 959 960 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1162 1163 1162 1163 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1341 1342 1341 1342 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1395 1396 1395 1396 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
###xml 549 557 <span type="species:ncbi:9606">patients</span>
###xml 628 636 <span type="species:ncbi:9606">patients</span>
###xml 1040 1048 <span type="species:ncbi:9606">patients</span>
###xml 1297 1305 <span type="species:ncbi:9606">patients</span>
In a similar way to chronic inflammatory diseases, plasma levels of sPLA2-IIA were shown to be elevated in patients with coronary artery disease (CAD) and to predict coronary events in asymptomatic patients or patients with stable angina (Kugiyama et al 1999). Moreover, increased plasma levels of sPLA2 in stable patients undergoing percutaneous coronary angioplasty (PCI) also provide independent prognostic information over other classic cardiovascular risk factors and clinical covariables (Liu et al 2003). The prognostic value of sPLA2-IIA in patients with acute coronary syndromes (ACS) was first described in a study of patients with unstable angina by Kugiyama and colleagues (2000). Increased plasma levels of sPLA2-IIA predicted recurrent coronary events, mainly revascularization procedures, independently of other established risk factors (Kugiyama et al 2000). Mallat and colleagues (2007) also evaluated the prognostic importance of plasma sPLA2-IIA levels and enzyme activity across the entire spectrum of ACS by recruiting patients from the Global Registry of Acute Coronary Events (GRACE). In this impressive study, they showed that plasma sPLA2 activity, in contrast to CRP or IL-18, was a major independent predictor of death and new or recurrent myocardial infarction (MI) in patients with ACS. Interestingly, total sPLA2-activity had a better prognostic value than the sPLA2-IIA antigen level.
###end p 26
###begin p 27
###xml 91 92 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 261 262 261 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 498 515 498 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">Mallat et al 2005</xref>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
However the study's most important finding was the fact that a single determination of sPLA2-activity, obtained during the two days after the onset of ischemic symptoms, provides powerful prognostic information in patients with ACS. The association between sPLA2 activity and the risk of subsequent death or MI was independent of the other known predictors of major adverse outcomes in patients with ACS, including the presence or absence of a history of MI or signs of heart failure at admission (Mallat et al 2005).
###end p 27
###begin p 28
###xml 96 97 96 97 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 133 164 133 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">Korotaeva and colleagues (2005)</xref>
###xml 193 194 193 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 324 344 324 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">Korotaeva et al 2005</xref>
###xml 258 263 <span type="species:ncbi:9606">human</span>
Additional evidence to confirm the importance of catalytic activity, as well as an elevated sPLA2-IIA antigen level, was gathered by Korotaeva and colleagues (2005). They demonstrated that sPLA2-IIA is involved in the development of restenosis after PTCA in human coronary arteries and in the generation of atherogenic LDL (Korotaeva et al 2005).
###end p 28
###begin p 29
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 234 254 234 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">Boekholdt et al 2005</xref>
###xml 256 273 256 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">Mallat et al 2007</xref>
Interestingly, sPLA2-IIA also seems to play an important role in predicting risk for coronary artery disease and adverse coronary events in healthy subjects, especially when combined with other pro-inflammatory risk factors like CRP (Boekholdt et al 2005; Mallat et al 2007).
###end p 29
###begin p 30
###xml 9 10 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
Thus sPLA2-IIA can be shown to be not only a mediator for localized inflammation but also a powerful independent predictor of adverse outcomes in patients with stable CAD, or in acute coronary syndromes.
###end p 30
###begin title 31
Angiotensin, LDL-peroxidation, and atherogenesis
###end title 31
###begin p 32
###xml 93 106 93 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">Keidar (1998)</xref>
###xml 419 420 419 420 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 582 599 582 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">Keidar et al 1995</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">2001</xref>
###xml 838 854 838 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">Mehta et al 2001</xref>
###xml 856 860 856 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">2002</xref>
###xml 1012 1023 1012 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">Keidar 1998</xref>
###xml 149 157 <span type="species:ncbi:9606">patients</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 611 616 <span type="species:ncbi:9606">human</span>
Early evidence of a potential role for angiotensin (Ang) II in LDL oxidation was gathered by Keidar (1998) who reported that the LDL of hypertensive patients was more responsive to oxidative modification than the LDL of normotensive subjects. Meanwhile, various interactions between Ang II and oxLDL have been demonstrated especially by the Keidar group. For example, Ang-II injection into apolipoprotein E-deficient (E0) mice led to increased cellular oxLDL uptake by their peritoneal macrophages (MPMs) via proteoglycan macrophage stimulation pathway, a process mediated by Il-6 (Keidar et al 1995, 2001). In human coronary endothelial cells, Ang-II enhanced the oxLDL-uptake by up-regulating the lectin-like receptor for oxLDL (LOX-1). This effect could be blocked by the angiotensin receptor blockers (ARBs) Losartan and Candesartan (Mehta et al 2001, 2002). Ang-II increased the cellular lipid peroxidation of MPMs by 50%-100%. Moreover, Ang-II enhanced scavenger receptor affinity to oxLDL on macrophages (Keidar 1998).
###end p 32
###begin p 33
###xml 73 74 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 267 268 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The effects of Ang-II are predominantly mediated via activation of the AT1-receptor which is coupled through guanine nucleotide binding proteins (G-proteins), adenylate cyclase and cyclic adenosine monophosphate (cAMP) as second messenger, as well as phospholipases A2, C and D and their products, arachidonic acid (AA), inositol triphosphate (IP3), or diacylglycerol (DG).
###end p 33
###begin p 34
###xml 267 268 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 351 368 351 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">Keidar et al 1995</xref>
The mechanism of Ang-II-mediated cellular lipid peroxidation involved Ang-II binding to its cellular receptor underlined by the fact that preincubation of the cells with the Ang-II antagonist, saralasin, completely inhibited this effect. Inhibitors of phospholipase A2, C and D also substantially reduced Ang-II-induced macrophage lipid peroxidation (Keidar et al 1995).
###end p 34
###begin p 35
###xml 17 18 17 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 116 133 116 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">Keidar et al 1999</xref>
###xml 171 172 171 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 179 196 179 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">Keidar et al 1997</xref>
###xml 213 240 213 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">Hayek and colleagues (2000)</xref>
###xml 566 582 566 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">Hayek et al 2000</xref>
###xml 641 657 641 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">Metha et al 2001</xref>
###xml 659 663 659 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">2002</xref>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
Interestingly, AT1-receptor blockade with Losartan inhibited LDL oxidation and macrophage cholesterol biosynthesis (Keidar et al 1999), and attenuated atherosclerosis in E0 mice (Keidar et al 1997). In a trial by Hayek and colleagues (2000), losartan therapy for a period of 4 weeks did not significantly affect the degradation of native LDL monocyte-derived macrophages (HMDM) derived from patients. However, Losartan therapy significantly reduced HMDM uptake of oxLDL as shown by a 78% reduction in oxLDL cell-association and a 21% reduction in oxLDL degradation (Hayek et al 2000), a finding which has been also confirmed for other ARBs (Metha et al 2001, 2002).
###end p 35
###begin p 36
All these findings suggested an integral link between angiotensin II (Ang-II) and its receptor mediated effects, and activation of pro-inflammatory and pro-atherogenic pathways which could further promote lipid peroxidation.
###end p 36
###begin title 37
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
sPLA2-IIA, the possible link between activated RAS, inflammation, and lipidperoxidation: a target for treatment?
###end title 37
###begin p 38
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 181 209 181 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">Cassis and colleagues (2007)</xref>
###xml 230 231 230 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 273 274 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 474 475 474 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 543 544 543 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 568 569 568 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 751 752 751 752 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 784 785 784 785 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 909 910 909 910 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 976 977 976 977 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1034 1035 1034 1035 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1069 1090 1069 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">Luchtefeld et al 2006</xref>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 649 652 <span type="species:ncbi:10116">rat</span>
As mentioned above, angiotensin II type 1 (AT1)-receptor blockade may reduce LDL-modification and atherosclerotic plaque formation in animal models of atherosclerosis. Furthermore, Cassis and colleagues (2007) demonstrated that AT1-mediated atherogenesis is dependent on AT1 expression in the vessel wall, and that the presence of this receptor in resident tissues is required to initiate AngII-induced atherosclerosis. Because of increasing evidence for involvement of sPLA2-IIA in modifying LDL, our group assessed whether ANG II, via its AT1-receptor, enhances sPLA2-IIA-dependent lipid peroxidation in vitro and in patients with CAD. Therefore, rat aortic smooth muscle cells were stimulated with ANG II. This stimulation resulted in enhanced sPLA2-IIA protein expression and sPLA2-IIA activity. LDL-peroxidation was consequently enhanced by ANG II. Interestingly, all these effects could be reduced by AT1-receptor blockade with losartan. Furthermore, ANG II-induced sPLA2 activity and LDL-peroxidation were prevented by the sPLA2-IIA activity inhibitor LY311727 (Luchtefeld et al 2006).
###end p 38
###begin p 39
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 186 187 186 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
These findings suggested that sPLA2-IIA activation could be the supposed link between activated RAS and lipidperoxidation, and that ANG II may elicit pro-atherosclerotic effects via sPLA2-IIA-dependent LDL-modification.
###end p 39
###begin p 40
###xml 160 161 160 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 314 315 314 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 637 658 637 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">Luchtefeld et al 2006</xref>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
In order to evaluate potential clinical implications of these findings, a small number of patients with angiographically documented CAD were treated with the AT1-receptor blocker irbesartan (300 mg/d) for 12 weeks. Blood samples were obtained from patients pre- and post-treatment and from healthy volunteers. SPLA2-IIA serum level and activity, circulating antibodies against oxidized LDL (oxLDL) and oxLDL, were determined in patients and found to be significantly increased compared to healthy volunteers. Irbesartan therapy reduced these markers of inflammation, whereas total cholesterol, HDL- and LDL-fractions remained unchanged (Luchtefeld et al 2006).
###end p 40
###begin p 41
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 221 222 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 358 359 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 469 470 469 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 500 508 <span type="species:ncbi:9606">patients</span>
Based on these findings we investigated further the potential effect of a combined treatment with pravastatin and irbesartan on oxLDL and sPLA2-IIA in a group of patients with CAD. We postulated that the addition of an AT1-receptor antagonist to the standard secondary prevention therapy with a statin might exert additional effects on LDL oxidation and sPLA2-IIA. We demonstrated that both treatment regimens comparably influenced LDL-cholesterol levels. However, sPLA2 activity was reduced only in patients treated with the adjunction of pravastatin and irbesartan. Consequently, only the combined treatment resulted in a significant reduction of ox-LDL levels independent of changes in LDL cholesterol (Divchev et al pers comm).
###end p 41
###begin p 42
###xml 49 50 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 216 223 <span type="species:ncbi:9606">patient</span>
All these findings suggest a possible role for AT1-receptor blockade in reducing LDL-peroxidation. Whether these effects can reduce the perpetuation of atherosclerosis and especially adverse cardiovascular events in patient with CAD remains to be elucidated in further studies.
###end p 42
###begin title 43
Conclusion
###end title 43
###begin p 44
###xml 41 42 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 154 155 154 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 312 313 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 566 567 566 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 626 627 626 627 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 819 824 <span type="species:ncbi:9606">human</span>
In conclusion, secretory phospholipases A2 (in general sPLA2-IIA) were shown to play an important role in atherogenesis. Furthermore, the activity of sPLA2-IIA is a powerful independent predictor of adverse events in stable patients with CAD and in ACS. Focusing on recent data, expression and activation of sPLA2-IIA in atherosclerotic lesions seemed to be one of the links between activated RAS, inflammation and the processes of lipid accumulation and lipid peroxidation in the vessel wall as main features of atherosclerosis. Therefore, direct inhibition of sPLA2-IIA through specific antagonists, or indirectly through AT1-receptor blockade, might be a new therapeutic option used to intervene in this detrimental process of plaque development. The confirmation of these therapeutic effects and their relevance in human atherosclerosis remain the foremost challenges.
###end p 44
###begin title 45
References
###end title 45
###begin article-title 46
###xml 34 37 <span type="species:ncbi:10116">rat</span>
Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1b in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kB and Ets transcription factors
###end article-title 46
###begin article-title 47
Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction
###end article-title 47
###begin article-title 48
Phospholipase A2-modified LDL is taken up at enhanced rate by macrophages
###end article-title 48
###begin article-title 49
###xml 76 82 <span type="species:ncbi:10090">murine</span>
Novel group V phospholipase A2 involved in arachidonic acid mobilization in murine P388D1 macrophages
###end article-title 49
###begin article-title 50
###xml 57 63 <span type="species:ncbi:10090">murine</span>
Inflammatory activation of arachidonic acid signaling in murine P388D1 macrophages via sphingomyelin synthesis
###end article-title 50
###begin article-title 51
Antisense inhibition of group II phospholipase A2 expression blocks the production of prostaglandin E2 by P388Dresden cells
###end article-title 51
###begin article-title 52
###xml 18 23 <span type="species:ncbi:9606">human</span>
Exogenously added human group X secreted phospholipase A2 but not the group IB, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells
###end article-title 52
###begin article-title 53
###xml 120 123 <span type="species:ncbi:9606">men</span>
###xml 128 133 <span type="species:ncbi:9606">women</span>
Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women The EPIC-Norfolk Prospective Population Study
###end article-title 53
###begin article-title 54
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology
###end article-title 54
###begin article-title 55
Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate Angiotensin II-induced atherosclerosis and aneurysms
###end article-title 55
###begin article-title 56
###xml 49 54 <span type="species:ncbi:9606">human</span>
Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute-phase response
###end article-title 56
###begin article-title 57
Secretory non-pancreatic phospholipase A2: influence on lipoprotein metabolism
###end article-title 57
###begin article-title 58
HDL modification by secretory phospholipase A2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism
###end article-title 58
###begin article-title 59
###xml 210 218 <span type="species:ncbi:9606">patients</span>
Personal communication Impact of a combined treatment of angiotensin II type 1 receptor blockade and HMG-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease
###end article-title 59
###begin article-title 60
Minimal oxidation and storage of low density lipoproteins result in an increased susceptibility to phospholipid hydrolysis by phospholipase A2
###end article-title 60
###begin article-title 61
Evidence that secretory phospholipase A2 plays a role in arachidonic acid release and eicosanoid biosynthesis by mast cells
###end article-title 61
###begin article-title 62
Regulation of secretory type-II phospholipase A2 and of lysophosphatidic acid synthesis
###end article-title 62
###begin article-title 63
Role of group IIA and group V secretory phospholipases A2 in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin
###end article-title 63
###begin article-title 64
Secretory phospholipases A2 as multivalent mediators of inflammatory and allergic disorders
###end article-title 64
###begin article-title 65
Circulating phospholipase A2 activity associated with sepsis and septic shock is indistinguishable from that associated with rheumatoid arthritis
###end article-title 65
###begin article-title 66
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans
###end article-title 66
###begin article-title 67
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 190 191 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 206 207 206 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 162 168 <span type="species:ncbi:10090">murine</span>
Cross-talk between cytosolic phospholipase A2 alpha (cPLA2 alpha) and secretory phospholipase A2 (sPLA2) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells: sPLA2 regulates cPLA2 alpha activity that is responsible for arachidonic acid release
###end article-title 67
###begin article-title 68
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation
###end article-title 68
###begin article-title 69
###xml 74 77 <span type="species:ncbi:10116">rat</span>
Purification and characterization of membrane-bound phospholipase A2 from rat platelets
###end article-title 69
###begin article-title 70
###xml 100 108 <span type="species:ncbi:9606">Patients</span>
Losartan Inhibits Cellular Uptake of Oxidized LDL by Monocyte-Macrophages from Hypercholesterolemic Patients
###end article-title 70
###begin article-title 71
Phagocytosis of lipase-aggregated low density lipoprotein promotes macrophage foam cell formation. Sequential morphological and biochemical events
###end article-title 71
###begin article-title 72
###xml 124 129 <span type="species:ncbi:9606">human</span>
Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1
###end article-title 72
###begin article-title 73
###xml 66 76 <span type="species:ncbi:10141">guinea pig</span>
Increased synthesis and secretion of a 14-kDa phospholipase A2 by guinea pig alveolar macrophages: dissociation from arachidonic acid liberation and modulation by dexamethasone
###end article-title 73
###begin article-title 74
Localization of non-pancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins
###end article-title 74
###begin article-title 75
Phospholipase A2 in vascular disease
###end article-title 75
###begin article-title 76
###xml 119 134 <span type="species:ncbi:10090">transgenic mice</span>
Role of group II secretory phospholipase A2 in atherosclerosis. 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIA phospholipase A2
###end article-title 76
###begin article-title 77
Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis
###end article-title 77
###begin article-title 78
Ang-II stimulates macrophage-mediated oxidation of LDL
###end article-title 78
###begin article-title 79
###xml 132 136 <span type="species:ncbi:10090">mice</span>
The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice
###end article-title 79
###begin article-title 80
Angiotensin, LDL peroxidation and Atherosclerosis
###end article-title 80
###begin article-title 81
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Ang-II atherogenicity in E0 mice is associated with increased cellular cholesterol biosynthesis
###end article-title 81
###begin article-title 82
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6
###end article-title 82
###begin article-title 83
###xml 113 118 <span type="species:ncbi:9606">human</span>
The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL
###end article-title 83
###begin article-title 84
Secretory group II phospholipase A2; a newly recognized acute-phase reactant with a role in atherogenesis
###end article-title 84
###begin article-title 85
Phospholipase A2 enzymes
###end article-title 85
###begin article-title 86
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease
###end article-title 86
###begin article-title 87
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris
###end article-title 87
###begin article-title 88
###xml 59 62 <span type="species:ncbi:10116">rat</span>
Intracellular localization of group II phospholipase A2 in rat vascular smooth muscle cells and its possible relationship to eicosanoid formation
###end article-title 88
###begin article-title 89
###xml 48 69 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Protection by group II phospholipase A2 against Staphylococcus aureus
###end article-title 89
###begin article-title 90
Role of group II secretory phopholipase A2 in atherosclerosis: 2. Potential involvment of biologically active oxidized phospholipids
###end article-title 90
###begin article-title 91
Properties and regulation of cytosolic phospholipase A2
###end article-title 91
###begin article-title 92
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention
###end article-title 92
###begin article-title 93
###xml 106 111 <span type="species:ncbi:9606">women</span>
###xml 116 119 <span type="species:ncbi:9606">men</span>
Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men
###end article-title 93
###begin article-title 94
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A(2)-dependent lipid peroxidation
###end article-title 94
###begin article-title 95
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes
###end article-title 95
###begin article-title 96
###xml 96 99 <span type="species:ncbi:9606">men</span>
###xml 104 109 <span type="species:ncbi:9606">women</span>
Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: The EPIC-NORFOLK Study
###end article-title 96
###begin article-title 97
###xml 77 82 <span type="species:ncbi:9606">human</span>
Facilitative interaction between angiotensin II and oxidized LDL in cultured human coronary artery endothelial cells
###end article-title 97
###begin article-title 98
Identification, regulation and function of a novel lectin like oxidized low density lipoprotein receptor
###end article-title 98
###begin article-title 99
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 124 139 <span type="species:ncbi:10090">transgenic mice</span>
Expression of human secretory group IIA phospholipase A2 is associated with reduced concentrations of plasma cholesterol in transgenic mice
###end article-title 99
###begin article-title 100
###xml 174 179 <span type="species:ncbi:9606">human</span>
Expression of secretory group IIA phospholipase A(2) in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues
###end article-title 100
###begin article-title 101
Secretory phospholipase A2 of group IIA: Is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?
###end article-title 101
###begin article-title 102
###xml 79 84 <span type="species:ncbi:9606">human</span>
Molecular nature of phospholipase A2 involved in prostaglandin I2 synthesis in human umbilical vein endothelial cells: possible participation of cytosolic and extracellular type II phospholipase A2
###end article-title 102
###begin article-title 103
New phospholipase A2 isozymes with a potential role in atherosclerosis
###end article-title 103
###begin article-title 104
Secretory phospholipase A2
###end article-title 104
###begin article-title 105
Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression
###end article-title 105
###begin article-title 106
###xml 151 154 <span type="species:ncbi:9606">men</span>
Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group
###end article-title 106
###begin article-title 107
Regulation of the angiotensin AT1 receptor by hypercholesterolaemia
###end article-title 107
###begin article-title 108
Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?
###end article-title 108
###begin article-title 109
###xml 61 66 <span type="species:ncbi:9606">human</span>
Interferon-g induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells: involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines
###end article-title 109
###begin article-title 110
###xml 124 127 <span type="species:ncbi:10116">rat</span>
Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat mesangial cells
###end article-title 110
###begin article-title 111
###xml 29 34 <span type="species:ncbi:9606">human</span>
Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A2
###end article-title 111
###begin article-title 112
Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors
###end article-title 112
###begin article-title 113
Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1
###end article-title 113
###begin article-title 114
Prostaglandin synthase-1 and prostaglandin synthase-2 are coupled to distinct phospholipases for the generation of prostaglandin D2 in activated mast cells
###end article-title 114
###begin article-title 115
###xml 120 125 <span type="species:ncbi:9606">human</span>
Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries
###end article-title 115
###begin article-title 116
Secretory phospholipase A2 type IIA and V in atherosclerosis: expression by vascular cells, localization in lesions and hydrolysis of lipoproteins
###end article-title 116
###begin article-title 117
Atherosclerosis - an inflammatory disease
###end article-title 117
###begin article-title 118
Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts
###end article-title 118
###begin article-title 119
Phospholipase A2 type II binds to extracellular matrix biglycan: modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes
###end article-title 119
###begin article-title 120
###xml 81 86 <span type="species:ncbi:9606">human</span>
Molecular basis for the association of group IIA phospholipase A2 and decorin in human atherosclerotic lesions
###end article-title 120
###begin article-title 121
###xml 125 128 <span type="species:ncbi:10116">rat</span>
Interleukin 1beta, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells
###end article-title 121
###begin article-title 122
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis
###end article-title 122
###begin article-title 123
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Presence of the M-type sPLA2 receptor on neutrophils and its role in elastase release and adhesion
###end article-title 123
###begin article-title 124
The expanding superfamily of phospholipase A2 enzymes: classification and characterization
###end article-title 124
###begin article-title 125
###xml 20 25 <span type="species:ncbi:9606">human</span>
High specificity of human secretory class II phospholipase A2 for phosphatidic acid
###end article-title 125
###begin article-title 126
Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification
###end article-title 126
###begin article-title 127
###xml 95 98 <span type="species:ncbi:10116">rat</span>
Induction of cyclooxygenase-2 by secretory phospholipases A2 in nerve growth factor-stimulated rat serosal mast cells is facilitated by interaction with fibroblasts and mediated by a mechanism independent of their enzymatic functions
###end article-title 127
###begin article-title 128
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients with stable coronary artery disease
###end article-title 128
###begin article-title 129
###xml 115 118 <span type="species:ncbi:9606">men</span>
###xml 123 128 <span type="species:ncbi:9606">women</span>
Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women
###end article-title 129
###begin article-title 130
Overexpression of Secretory Phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I*
###end article-title 130
###begin article-title 131
###xml 48 49 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress
###end article-title 131
###begin article-title 132
Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome
###end article-title 132
###begin article-title 133
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
On the diversity of secreted phospholipases A(2). Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes
###end article-title 133
###begin article-title 134
Expression of type-II phospholipase A2 in alveolar macrophages: down-regulation by an inflammatory signal
###end article-title 134
###begin article-title 135
Secretory phospholipase A2 enzymes in atherogenesis
###end article-title 135
###begin article-title 136
###xml 12 13 12 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Group V sPLA2 hydrolysis of LDL results in spontaneous particle aggregation and promotes macrophage foam cell formation
###end article-title 136
###begin article-title 137
###xml 126 142 <span type="species:ncbi:562">Escherichia coli</span>
###xml 148 154 <span type="species:ncbi:9986">rabbit</span>
Purification of a cellular (granulocyte) and an extracellular (serum) phospholipase A2 that participate in the destruction of Escherichia coli in a rabbit inflammatory exudate
###end article-title 137
###begin article-title 138
An essential role for lysophosphatidylcholine in the inhibition of platelet aggregation by secretory phospholipase A2
###end article-title 138

